Halozyme Therapeutics (Nasdaq: HALO) announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE